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Abstract
The relation between bone remodelling and energy 
expenditure is an intriguing, and yet unexplained, chal-
lenge of the past ten years. In fact, it was only in the 
last few years that the skeleton was found to function, 
not only in its obvious roles of body support and pro-
tection, but also as an important part of the endocrine 
system. In particular, bone produces different hor-
mones, like osteocalcin (OC), which influences energy 
expenditure in humans. The undercarboxylated form of 
OC has a reduced affinity for hydroxyapatite; hence it 
enters the systemic circulation more easily and exerts 
its metabolic functions for the proliferation of pancre-
atic β-cells, insulin secretion, sensitivity, and glucose 
tolerance. Leptin, a hormone synthesized by adipo-
cytes, also has an effect on both bone remodelling and 
energy expenditure; in fact it inhibits appetite through 
hypothalamic influence and, in bone, stimulates os-
teoblastic differentiation and inhibits apoptosis. Leptin 
and serotonin exert opposite influences on bone mass 
accrual, but several features suggest that they might 
operate in the same pathway through a sympathetic 
tone. Serotonin, in fact, acts via  two opposite pathways 
in controlling bone remodelling: central and peripheral. 
Serotonin product by the gastrointestinal tract (95%) 
augments bone formation by osteoblast, whereas 
brain-derived serotonin influences low bone mineral 
density and its decrease leads to an increase in bone 
resorption parameters. Finally, amylin (AMY) acts as a 
hormone that alters physiological responses related to 
feeding, and plays a role as a growth factor in bone. 
In vitro  AMY stimulates the proliferation of osteoblasts, 
and osteoclast differentiation. Here we summarize the 
evidence that links energy expenditure and bone re-
modelling, with particular regard to humans.
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INTRODUCTION
Every part of  the human body communicates and co-
operates with each other in a specific way, and with 
unique functions, and bone is not an exception. The 
skeleton was considered for a long time just a “stone” 
with movement function, a reserve of  minerals, and the 
home of  the hematopoietic system; only in recent years 
has the idea that it is in deep contact with other systems, 
such as the immune and cardiovascular systems, been de-
veloped[1,2]. More recently, the skeleton’s ability to regulate 
energy expenditure has been described, and bone is now 
also considered as an endocrine organ.
An important feature of  hormonal regulation is that 
there are some cells, controlled by a feedback loop, that 
produce hormones; these hormones send specific signals 
to other cells and are responsible for several functions 
in the human organism. Bone is a target for different 
hormones that regulate both bone metabolism and re-
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modeling through a central control. The fact that energy 
metabolism affects bone mass accrual by acting through 
a neuronal relay on one cell type, the osteoblasts, raised 
the testable hypothesis that, in turn, the osteoblasts might 
secrete one or more hormones affecting energy metabo-
lism[3].
The skeleton, in particular, secretes two hormones: 
fibroblast growth factor 23 and osteocalcin (OC); OC is 
an osteoblast-specific protein that influences pancreatic 
β-cell proliferation, insulin expression, secretion, sensitiv-
ity, and energy expenditure[4]. Mice knock-out for OC, 
created by Ducy et al[5], appear mildly hyperglycaemic 
and have slightly increased visceral fat; the opposite phe-
notype null for the Esp gene, which encodes a tyrosine 
phosphatase that hampers glucose metabolism by inhibit-
ing OC functions, instead displays improved glucose tol-
erance. An even more intimate relationship between skel-
eton and energy metabolism was demonstrated by recent 
genetic experiments that found that leptin, an adipocyte-
derived hormone, inhibits insulin secretion by decreasing 
the production of  undercarboxylated osteocalcin, and is 
also involved in osteoblast differentiation[6]. Moreover, se-
rotonin, which is produced by neurons of  the brainstem 
and by the enterochromaffin cells of  the duodenum, 
controls bone remodeling[7]. The relationship between 
energy expenditure and bone is still controversial; studies 
on humans are few, and the majority of  data have been 
derived by animal models. 
This review aims to summarize the evidence linking 
energy metabolism and skeleton, with particular attention 
to humans.
CENTRAL CONTROL OF BONE MASS: 
LEPTIN
Data in animals
Leptin, the protein product of  the obese gene (Ob or 
Lep), is a hormone synthesized by adipocytes that signals 
available energy reserves to the brain, and thereby influ-
ences development, growth, metabolism, and reproduc-
tion. In mammals, leptin functions as a signal for fat 
reserves: circulating leptin fluctuates in proportion to fat 
mass, and acts on the hypothalamus to suppress food in-
take[8].
When adipose tissue is abundant, leptin levels rise as 
a result energy expenditure and sympathetic activity in-
creases. In comparison, when adipocyte mass decreases, 
energy expenditure, temperature, and reproductive func-
tion are down-regulated. As proof  of  this fact, Ob-/Ob-
mice are obese, hypogonadal, and diabetic[9]. Ob genes 
were recently isolated from several fish and two amphib-
ian species. While vertebrate leptins largely differ in their 
primary amino acid sequences, they have similar tertiary 
structures and potencies when tested in vitro on heterolo-
gous leptin receptors (LepRs)[8,10-12]. Leptin acts through 
a leptin receptor that is a member of  the type Ⅰ cytokine 
receptor family[13]. There are different isoforms of  this 
receptor that are produced by alternative splicing of  
the transcript from the LepR gene, defined as: LepRa, 
LepRb, LepRc, LepRd and LepRf; these isoforms have in 
common an extracellular domain of  800 amino acids and 
a transmembrane domain of  34 amino acids, although 
the intracellular domain is variable and characteristic for 
each of  the isoforms; in particular, LepRb seems to be 
suitable for all leptin actions[13-15]. In fact, in mammals, 
LepRb is highly expressed in the hypothalamus and at 
lower levels in several other tissues, including the liver, kid-
ney, lung, stomach, pancreatic cells, and immune cells[16-20]. 
Leptin’s role in energy balance/body weight control is 
mediated by LepRb expressed in the brain[21,22]. Leptin 
binds to LepRs in the plasma membrane of  this specific 
cell, activating several intracellular signaling pathways[23]. 
Vertebrate LepRs signals via the Janus kinase (Jak) and 
signal transducer, and is the activator of  the transcrip-
tion (STAT) pathway. Three tyrosine residues located 
within the LepR cytoplasmic domain are phosphorylated 
by Jak2, and are constitutively associated with mouse 
LepRb at membrane-proximal residues located within the 
cytoplasmic domain and are required for the activation 
of  SH2-containing tyrosine phosphatase-2, STAT5, and 
STAT3 signaling[8]. These tyrosines are conserved from 
fish to mammals, demonstrating their critical role in sig-
naling by LepR. 
Leptin can also be considered as a growth factor, with 
the ability to directly enhance the development of  he-
mopoietic precursor cells, myoblast-like cells, and lung 
cells. Moreover, Kume et al[2] observed that leptin has an-
giogenic effects on vascular musculoskeletal endothelial 
cells. This could be critical during fetal development; in 
fact, leptin and its receptor are produced by the human 
placenta[1,24]. Both leptin and its receptors were found 
in murine cartilage and bone, especially in chondrocytes 
near the vascular system. This observation may explain 
the angiogenic properties of  leptin[2]. In addition, leptin 
increases both the proliferation and differentiation of  the 
chondrocyte population of  skeletal growth centers in or-
gan cultures through the insulin-like growth factors (IGF) 
and the regulation of  receptor IGF expression[25,26].
Dixit et al[27] showed that leptin is a potent stimulator 
of  growth hormone secretion, both at the central pitu-
itary level and at the peripheral level, from lymphocytes. 
Experimentally, leptin has a positive effect on bone mass 
when infused intravenously, but a negative one after in-
tracerebroventricular administration[28,29]. These opposite 
effects of  leptin were brilliantly demonstrated by Thom-
as[30] using a parabiosis experiment. Further experiments 
demonstrated that leptin inhibits appetite through the 
arcuate nucleus, and bone mass through the ventromedial 
hypothalamus nucleus. These experiments indicate that 
hypothalamic integrity is required in bone regulation[29,31]. 
Different studies, using a human stromal cell line, dem-
onstrated that cells of  osteoblastic lineage are targets for 
leptin action, as they actively expressed both forms of  
leptin receptors[32-35].
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Although leptin plays a critical role in starvation-
induced T-cell-mediated immunosuppression, little is 
known about its role in B-cell homeostasis under starva-
tion conditions. A Japanese study show the alteration of  
B-cell development in the bone marrow of  fasted mice, 
characterized by a decrease in pro-B, pre-B, and immature 
B cells, and an increase in mature B cells. Interestingly, 
an intracerebroventricular leptin injection was sufficient 
to prevent the alteration of  B-cell development in fasted 
mice[36].
Data in humans
In humans there are some reports linking leptin with 
bone mass, even if  studies in humans are biased by con-
founding factors. Some data obtained using animal mod-
els were confirmed by human studies, and it is generally 
accepted that body weight is a major determinant of  
bone density; in fact, obesity is generally accompanied by 
increased bone strength and obese persons have stronger 
bones and lose bone tissue at a slower pace[37]. Serum 
leptin levels positively correlate with the mass of  adipose 
tissue, and show a weak correlation with bone density in 
humans[38]. Clinical studies on animals and humans show 
that leptin access to the hypothalamic centre, which has 
a negative effect on appetite and bone mass, is limited by 
the blood brain barrier[37-39]. This access implies a satura-
ble transport system involving the LepRa receptors (with 
a shorter intracellular domain than that of  its effective re-
ceptor LepRb)[39]. Renal failure increases the leptin serum 
level above the concentration which may lead to satura-
tion of  leptin transport to the brain[38]. In fact, Ghazali 
et al[38] showed, in an hemodialysis population, that only 
when the serum leptin levels are above this threshold is 
there is a sparing effect in bone.
Stimulated by animal studies that describe the rela-
tionship between a lack of  leptin in mice and low sym-
pathetic tone, the pathway of  leptin’s indirect control of  
bone mass has also been investigated in humans[40]. Visit-
sunthorn et al[41] observed that human reflex sympathetic 
dystrophy is characterized by a rapid onset of  osteopo-
rosis in the affected region, with labile vasomotor activ-
ity, trophic skin changes, pain, and swelling, because of  
deregulated sympathetic tone. In some cases, β-blockers 
resolve reflex sympathetic dystrophy-associated symp-
toms and osteopenia. Outside the context of  reflex 
sympathetic dystrophy, people receiving β-blockers ex-
perience 24%-32% reductions in the risk of  fractures, as 
shown in several large studies[42-45]. Schlienger et al[46] sug-
gest that use of  β-blockers is associated with a reduced 
risk of  fractures, taken alone or in combination with 
thiazide diuretics. Thomas[30] observed that, in human 
cell cultures, leptin induced activation of  the mitogen-
activated protein kinase cascade could be critical, because 
it stimulated both osteoblastic differentiation from bone 
marrow precursors and phosphorylation of  peroxisome 
proliferator-activated receptor-γ, which has been shown 
to inhibit adipogenesis[47,48]. In addition, leptin could 
enhance osteoblastic activity by inhibiting apoptosis, 
stimulating mineralization, and inhibiting support of  os-
teoclastogenesis, as shown in primary human osteoblast 
cultures[49]. Through direct positive effects on osteoblast 
differentiation, leptin might modulate bone remodelling. 
It has also recently been shown in human stromal cells 
that leptin inhibits the expression of  the receptor activa-
tor of  nuclear factor-κB-ligand, the major downstream 
cytokine controlling osteoclastogenesis[50].
Leptin serum levels have different effects in differ-
ent human demographics. In premenopausal women, a 
higher proportion of  fat and a higher leptin concentra-
tion are negatively associated with bone mass[51]. Inter-
estingly, in postmenopausal women, leptin levels were 
significantly lower in women with vertebral fractures 
than those without, and an increase in fat mass negatively 
predicts fracture presence[52]. A recent study showed that 
obese children have altered bone turnover[53]. Conversely, 
Farooqi et al[54] reported in three obese children congeni-
tally deficient in leptin, that whole-body bone mineral 
content (BMC) and bone mineral density (BMD) were 
normal for their age and gender, despite very high weight 
and advanced bone ossification. After leptin therapy ad-
ministered for up to four years, BMC, BMD, and skeletal 
maturation increased normally, although weight and fat 
mass dramatically decreased, suggesting counteracting 
and beneficial effects of  leptin therapy on the skeleton[54]. 
Although these different studies converge to support the 
role of  leptin as a regulator of  bone metabolism, under-
standing the complexity of  its multiple pathways to the 
skeleton requires further investigation.
SEROTONIN AND ITS TWO IDENTITIES 
Production and secretion
Serotonin plays a major role in controlling bone remod-
elling via two distinctly opposite pathways; in fact, it is 
synthesized by two different genes and plays an antago-
nist function on bone mass[55]. The major site (95%) of  
serotonin production is the gastrointestinal tract by the 
tryptophan hydroxylase (Tph1) gene[56]. The importance 
of  gut-derived serotonin was identified recently, thanks 
to studies on the lipoprotein receptor-related proteins 5 
(Lrp5) receptor, a member of  the low density lipopro-
tein receptor family; the signal mediated by Lrp5 in an 
unknown cell type increase bone formation by osteob-
lasts[57]. Brain-derived serotonin produced by the Tph2 
gene also influences bone mass, and the severe low bone 
mass observed in the absence of  Tph2 results from an 
effect on both bone resorption and formation, mediated 
by an increased sympathetic tone. In the brain, synthesis 
of  serotonin by neurons which express the leptin recep-
tor is negatively controlled by leptin through its effects 
on Tph2 expression[58]. Patients taking synthetic serotonin 
reuptake inhibitors chronically (a class of  drugs increas-
ing extracellular serotonin concentration throughout the 
body) have reduced bone mass[59].
192 November 18, 2012|Volume 3|Issue 11|WJO|www.wjgnet.com
D'Amelio P et al . Energy metabolism and skeleton: Reciprocal interplay
Energy expenditure and serotonin
The signalling of  serotonin to bone is attributed to differ-
ent receptors: Htr1b signalling decreased bone formation, 
in contrast with Htr2c which inhibits the synthesis of  
epinephrine and has a decreased sympathetic tone; thus, 
this results in increased formation and decreased bone 
resorption[55]. The decrease in bone formation and the in-
crease in bone reabsorption in Tph2-/-mice mirrors the 
phenotype of  2 adrenergic receptor knocked-out mice. 
This feature suggested that the bone phenotype of  the 
mice lacking serotonin in the brain could be secondary to 
an increase in the sympathetic signal in osteoblasts[60].
Serotonin absence in the brain resulted in a phenotype 
with severe low bone mass, affecting axial and appen-
dicular skeleton, while bone length and width were unaf-
fected[7]. This was secondary to a decrease in bone forma-
tion parameters (osteoblast numbers and bone formation 
rate) and to an increase in bone resorption parameters 
(osteoclast surface and circulating levels of  deoxypridi-
noline, a degradation product of  type Ⅰ collagen and a 
biomarker of  bone resorption)[61]. Even if  leptin and se-
rotonin exert opposite influences on bone mass accrual, 
several features suggested that they might operate in the 
same pathway: for instance serotonin, like leptin, regu-
lates bone mass through their action on sympathetic tone 
and requires ventromedial hypothalamic neuron integrity 
to achieve its functions[7]. This fact raised the prospect 
that axonal projections emanating from Tph2- expressing 
neurons reach arcuate nuclei to regulate these functions[7]. 
Analysis verified that neurons of  the arcuate nuclei were 
target by serotoninergic innervation emanating from the 
brainstem, an observation confirmed in Tph2+/-mice 
by retrograde labelling of  the projections reaching the 
serotoninergic neurons of  the brainstem[7]. Experimental 
evidence supports the notion that the appetite phenotype 
of  the Tph 2-/-mice was caused, at least in part, by an 
increase in melanocortin signaling mediated through the 
Htr1a and Htr2b receptors, and involves melanocortin 
signaling[7]. Several reasons led us to ask whether the appe-
tite and energy expenditure phenotypes of  the Ob-/-mice 
were serotonin dependent: the first is that the conjunc-
tion of  a decrease in appetite and an increase in energy 
expenditure is the mirror image of  what is seen in mice 
lacking leptin signaling, the second is that leptin inhibi-
tion of  serotonin synthesis in the brainstem is the mecha-
nism used by this hormone to inhibit bone mass accrual, 
and the third is that no molecular mechanism has been 
identified so far to explain the common control of  bone 
mass and energy metabolism[7]. Figure 1 summarizes the 
relationships between leptin and serotonin. 
Lrp5 and bone formation
One of  the most studied regulators of  bone remodelling 
is low-density lipoprotein (LDL)-Lrp5, which a loss of  
function mutation causes osteoporosis pseudoganglioma 
(OPPG), a rare disease characterized by decreased bone 
formation and blindness[62], while activating mutations 
causing high bone mass syndrome[57]. Lrp5 can enhance 
Wnt (the vertebrate homolog of  Wingless in Drosophila) 
and canonical signaling in cultured cells. The blindness 
observed in OPPG patients and Lrp5-/-mice is caused 
by the deregulation of  Wnt canonical signaling during eye 
development[63]. Binding of  Wnt to Frizzled (Fz) recep-
tors, expressed by osteoblasts, causes intracellular β-catenin 
stabilization. In cooperation with lymphoid enhancer fac-
tor/T cell factor transcription factors, β-catenin activates 
transcription of  osteoprotegerin (OPG), a cytokine se-
creted by osteoblasts that decreases bone resorption.
Inactivation of  Lrp5 and activation of  β-catenin, 
the molecular node of  Wnt signalling, affects different 
transcriptomes in osteoblasts[63]. Lastly, inactivation of  
Lrp5 in osteoblast progenitors does not influence bone 
homeostasis, whereas inactivation of  canonical Wnt sig-
naling does[64]. Taken together, these observations sug-
gest that Lrp5 and canonical Wnt signaling use different 
mechanisms to regulate osteoblast functions. It is as-
sumed that Lrp5 is a coreceptor for Wnt proteins[65]; as a 
result, OPPG and high bone mass syndrome are viewed 
as Wnt-related diseases[66]. Some observations, however, 
change this view. Firstly, there is no overt skeletal defect 
in Lrp5-/- embryos; secondly, a function gain muta-
tion in Lrp5 does not cause bone tumors as the activa-
tion of  Wnt signaling does in other organs[67]; and lastly, 
osteoblast-specific loss and a function gain mutation in 
β-catenin, the molecular node of  canonical Wnt signaling, 
does not affect either bone formation or the expression 
of  genes deregulated upon Lrp5 inactivation. Analyses of  
a microarray experiment comparing bones from Lrp5-/- 
and wild type littermate mice provided the completely 
unexpected clue that the gene most highly overexpressed 
in Lrp5 deficient bone was Tph1, for which expression in 
the gut is increased in the absence of  Lrp5, as are serum 
serotonin levels in Lrp5 deficient patients or mice[68].
The only genes whose expression was decreased in 
Lrp-/-mice bones were the regulators of  cell prolifera-
tion CicD1, D2 and E1[69]. Lrp5-/-osteoblasts prolifer-
ated as well as wild-type cell ex vivo, and the discrepancy 
between the in vivo and ex vivo proliferation abilities of  the 
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Figure 1  Schematic representation of the relationship between fat tissue, 
brain, gut, and bone mediated by leptin and serotonin.
Lrp5-/-osteoblasts indicated that Lrp5 loss of  function 
mutations affected osteoblast proliferation through ex-
tracellular signals that can not originate from osteoblasts; 
in other words Lrp-5 related bone diseases may not origi-
nate from bones[69].
HOW BONE CONTROLS ENERGETIC 
METABOLISM: OC
OC is a 5 kDa protein produced by the skeleton and is 
the most prevalent non-collagenous protein in bone[70]. It 
has several features as a hormone, but moreover it rep-
resents one of  the most important links between bone 
tissue and energy metabolism. OC is one of  the very few 
osteoblasts-specific proteins, and it is subject to post-
translational carboxylation on three or four glutamic resi-
dues, depending on the species.
Vitamin K is a co-factor for the enzyme glutamate 
carboxylase, required for carboxylation of  the Gla-
containing proteins in the coagulation cascade and for 
carboxylation of  OC[71]. Lower dietary levels of  vitamin 
K are associated with increased levels of  undercarboxyl-
ated osteocalcin (ucOC), and vitamin K supplementation 
reduces ucOC[72]. Warfarin, an anti-coagulant which ac-
tion is based on inhibition of  the vitamin K dependent 
carboxylase, also regulates mRNA expression of  OC, and 
this fact makes interpretation of  warfarin treatment stud-
ies more complex[73]. Decarboxylation allows the molecule 
to tightly bind the calcium ions in hydroxyapatite[74-76]; 
ucOC has a reduced avidity for hydroxyapatite, and so 
it enters the systemic circulation more easily[77]. There is 
a feed forward regulation loop that links insulin, bone 
resorption, and OC. Insulin signaling in OPG expression 
and the decrease in the OPG/receptor activator of  the 
nuclear factor-kappa B ligand ratio results in an increased 
acidification of  the resorption lacunae. The acidic pH is 
sufficient to activate the OC molecules stored in the bone 
extracellular matrix. The ucOC promotes insulin sensitiv-
ity in peripheral organs and stimulates insulin secretion 
by pancreatic β-cells (Figure 2).
Work by Karsenty et al[77] suggested that bone could 
influence glucose homeostasis by acting as an endocrine 
organ; this concept came from the observation that mice 
which were OC deficient were not only fat, but  also 
had higher blood glucose, lower serum insulin, impaired 
glucose-stimulated insulin secretion, and poor glucose 
tolerance as compared to wild type mice. These observa-
tions remained unexplained for some years until the same 
investigators, in the course of  experiments in which they 
were ablating bone-specific proteins in mice, noted the 
opposite phenotype in mice null for Esp gene[78], which 
encodes an osteotesticular protein tyrosine phosphatase 
(OST-PTP) that hampers glucose metabolism by inhibit-
ing OC endocrine functions.
When Esp-/- were bred, a considerable number of  
deaths in newborns were observed, which resulted from 
severe hypoglycemia[77]. Studies of  surviving mice showed 
increased pancreatic cell size, β-cells number, circulat-
ing insulin levels and sensitivity, decreased body fat, and 
increased expression of  insulin target genes in the liver 
and muscles[77]. This phenotype was identical in global 
knock-out and osteoblast specific Esp knock-out mice, 
and opposite to OC null mice. OC-/-mice have increased 
visceral fat and glucose intolerance, decreased insulin 
levels, islet cell proliferation, and insulin content, similarly 
to mice over-expressing OST-PTP in osteoblasts. These 
findings suggest osteoblasts as a source of  a humoral fac-
tor that influences energy metabolism[77]. In vivo, OC can 
favor proliferation of  pancreatic β-cells, insulin, adipo-
nectin expression in β-cells, and adipocytes[77]. In humans, 
the insulin receptor is a substrate of  OST-PTP, the pro-
tein encoded by Esp. This raised the testable hypothesis 
that PTP-1B expressed in human osteoblasts could be 
the functional human homologue of  the Esp gene[77]. El-
evated levels of  both carboxylated and undercarboxylated 
forms of  OC were associated with improved glucose tol-
erance in healthy men given an oral glucose load[77].
In older healthy men, serum OC concentrations were 
inversely associated with blood markers of  the dysmeta-
bolic phenotype and measures of  adiposity[79]. There is no 
univocal explanation of  how parathyroid hormone (PTH) 
influences glucose metabolism in humans and mice, but it 
has been observed that hyperparathyroidism could impair 
glucose tolerance through a different mechanism, such 
as an increased intracellular free calcium concentration 
(which decreases insulin sensitivity by decreasing insulin-
dependent glucose transport)[80,81], or decreased plasma 
phosphate levels (which decrease insulin sensitivity, as 
insulin-dependent glucose uptake is closely related to 
phosphate uptake)[82], or down regulation of  insulin re-
ceptors, or PTH per se[83]. The administration of  intermit-
tent subcutaneous PTH (1-34 Teriparatide or 1-84) has 
been recently available for osteoporosis treatment[84,85].
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Figure 2  Schematic representation of the interaction between bone and 
glucose tolerance mediated by insulin and undercarboxylated osteocalcin.
The intermittent administration of  this molecule 
in osteoporotic patients has an anabolic effect on the 
skeleton in contrast with the catabolic effect of  continu-
ous PTH excess in hyperparathyroidism. It has been 
previously reported that there is either an acute, sub-
clinical adverse effect of  PTH 1-34 on stimulated glucose 
levels[86] or no effect of  this hormone on glucose toler-
ance[87].
It is known the ability of  the treatment with inter-
mittent PTH is to modify the secretion of  OC from 
the osteoblasts and, at the time of  writing, many stud-
ies been set to established if  the secretion of  ucOC is 
influenced by the therapy and if, consequently, therapy 
with PTH can interfere with the ability of  the skeleton to 
regulate energetic metabolism. Schafer et al[88] investigated 
whether changes in ucOC during osteoporosis treatment 
with PTH are associated with changes in metabolic pa-
rameters. They found that not only the median total and 
undercarboxylated levels increased with PTH 1-84 treat-
ment, but also the body weight and fat mass decreased, 
and this change was positively correlated with a change 
in adiponectin. Pittas et al[79] reported that in older adults, 
total serum OC was inversely associated with body fat, 
fasting glucose, and fasting insulin. In a cohort of  men 
and postmenopausal women with type 2 diabetes mel-
litus, undercarboxylate osteocalcin inversely correlated 
with percentage trunk fat and haemoglobin A1c[89].
AMYLIN IN THE PERIPHERY
Amylin (AMY) is a 37-amino acid peptide that belongs to 
the calcitonin (CT) family and has evolutionary links with 
insulin. It is co-secreted with insulin by pancreatic β-cells 
and has been considered a partner peptide in the etiology 
of  diabetes-associated complications and related condi-
tions[90]. While the soluble monomeric form of  AMY acts 
as a hormone that alters physiological responses related 
to feeding and acts as a growth factor, the less soluble 
and insoluble polymeric forms may contribute to the 
establishment of  a pathophysiological pathway to overt 
diabetes[90]. Research into the potential effect of  AMY 
on BMD followed the observation that a large number 
of  diabetic people are osteopenic. In vitro AMY acted 
as a grow factor in bone for the proliferation of  osteo-
blasts[91], and recently it was demonstrated that it also acts 
in osteoclast differentiation[92].
In foetal rat osteoblasts, intact AMY and 1-8 AMY 
stimulates cell proliferation, but AMY 8-37, COOH termi-
nally deaminated AMY and reduced AMY, by acting in an 
antagonist manner[93]. In osteoblasts, AMY acts through 
a increase of  cyclic adenosine monophosphate and the 
activation of  mitogen-activated protein kinase and protein 
kinase C[93]. Data on humans are lacking in the literature; 
it is known that aging is associated with impairment of  
AMY release from pancreatic beta cells, but further stud-
ies are needed to verify this[94]. It is also known that aging 
is associated with an impairment of  AMY release from 
pancreatic β-cells[95]. In previous studies it was demon-
strated that there were significantly lower unreduced AMY 
plasma levels in patients with osteoporosis than in those 
with type Ⅱ DM and healthy controls[96].
More recently, the analyses of  calcitonin-related gene-
deletion mouse models have demonstrated that AMY 
is a factor that inhibits osteoclastogenesis and reduces 
the rate of  osteolysis[97-99]. CT was shown to decrease 
osteoclast acidification and is also able to inhibit acid 
phosphatase secretion[100]. CT gene-related peptides a 
and β, produced by alternative splicing of  the CT gene, 
have dual roles: prevention of  bone reabsorption in hy-
percalcemic states and regulation of  bone formation. On 
the other hand, there is an increase in the rate of  bone 
formation that seems to contradict previous findings 
concerning the activity of  osteoclasts[90].
CONCLUSION
Here we summarize numerous studies that demonstrate 
a deep interaction between the skeleton, glucose, and en-
ergy metabolism (Figure 3). Many studies show that bone 
shares hormonal and molecular pathways with glucose 
and fat metabolism. The skeleton is subjected to various 
influences from fat tissue and glucose metabolism and 
is able to regulate these two systems in turn. Bone must 
therefore be considered as an endocrine organ with mul-
tiple functions, and not only a support for muscles. In 
the recent years this role has been confirmed in humans, 
and some studies, although controversial, demonstrate a 
correlation between bone endocrine function, body fat 
distribution and percentage, and glucose metabolism.
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